---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-089815"
form_type: "8-K"
ticker: "GPCR"
cik: "0001888886"
company_name: "Structure Therapeutics Inc."
filed_at: "2023-08-10T23:59:59+00:00"
generated_at: "2026-06-11T19:29:10.696808+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Structure Therapeutics reports Q2 net loss $23.3M; completes Phase 2a enrollment for GSBR-1290

## Summary
- Net loss of $23.3M for Q2 2023 vs $15.5M for Q2 2022; includes $1.7M stock-based compensation.
- Cash, equivalents and short-term investments of $224.6M at June 30, 2023; expected to fund operations through at least 2025.
- R&D expenses $19.4M for Q2 2023 vs $10.2M in Q2 2022, driven by GLP-1R franchise advancement.
- Completed enrollment in 12-week Phase 2a study of oral GLP-1 agonist GSBR-1290 (94 participants); topline data expected latter half Q4 2023.
- Appointed Ted W. Love, M.D. to Board of Directors; preparations underway for global Phase 2b study in 2024.

## SEC filing metadata
- accession: 0001104659-23-089815
- form_type: 8-K
- ticker: GPCR
- cik: 0001888886
- company_name: Structure Therapeutics Inc.
- filed_at: 2023-08-10T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1888886/000110465923089815/0001104659-23-089815-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1888886/000110465923089815/tm2323266d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-089815
- JSON: https://secwatch.observer/filing/0001104659-23-089815.json
- Plain text: https://secwatch.observer/filing/0001104659-23-089815.txt

## Key facts
- Earnings Releases
  Structure Therapeutics Inc. reported the second quarter ended June 30, 2023 results: net income Net loss totaled $23.3 million.
  - Period: the second quarter ended June 30, 2023
  - Net income: Net loss totaled $23.3 million
  - Result: reported results
  source text: Structure Therapeutics Inc. (the “Company”) issued a press release providing a corporate update and announcing its financial results for the second quarter ended June 30, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1888886/000110465923089815/0001104659-23-089815-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.